← Leaderboards
Min Lu
Weill Medical College Of Cornell Univ
$17,094,037
Attributed
$19,041,020
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$19,041,020 · 18
By mechanism
R01$9,920,903 · 4
R21$4,378,145 · 9
U19$1,867,962 · 2
R33$1,848,010 · 1
R56$1,026,000 · 2
Top collaborators
- Daniel Malamud7 shared
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- James M Binley$18,370,920
- John P Moore$51,152,802
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureHiv-1Hiv Envelope Protein Gp120DesignInhibitor/AntagonistLeadPeptidesCellsPropertyBinding (Molecular Function)SpecificityPreventBaseVariantMembrane FusionMediatingOryctolagus CuniculusIn VivoNeutralizing AntibodyTransmission ProcessInfectionGlycoproteinsCcr5 GeneIn Vitro
Grant awards (62)
Structural Refinement Core$252,417
U19 · FY2018 · AI · contact PI
Structural Refinement Core$139,296
U19 · FY2018 · AI · contact PI
Structural Refinement Core$397,456
U19 · FY2017 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$723,472
R01 · FY2016 · AI · contact PI
Structural Refinement Core$371,977
U19 · FY2016 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$732,548
R01 · FY2015 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$477,000
R33 · FY2015 · AI · contact PI
Structural Refinement Core$355,387
U19 · FY2015 · AI · contact PI
Development of novel small-molecule inhibitors of HIV-1 fusion as microbicides$636,000
R56 · FY2014 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$492,342
R01 · FY2014 · AI · contact PI
Structural Refinement Core$351,429
U19 · FY2014 · AI · contact PI
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens$196,763
R21 · FY2014 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$492,342
R01 · FY2013 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$448,380
R33 · FY2013 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$448,380
R33 · FY2013 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$1
R01 · FY2013 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$896,761
R01 · FY2012 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$249,583
R33 · FY2012 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$224,667
R33 · FY2012 · AI · contact PI
Development of an HIV-1 entry inhibitor pre-drug as a microbicide$182,085
R21 · FY2012 · AI · contact PI
Development of an HIV-1 entry inhibitor pre-drug as a microbicide$31,144
R21 · FY2012 · AI · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$556,500
R01 · FY2011 · AI · contact PI
Development of an HIV-1 entry inhibitor pre-drug as a microbicide$214,500
R21 · FY2011 · AI · contact PI
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens$185,899
R21 · FY2011 · AI · contact PI
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens$7,151
R21 · FY2011 · AI · contact PI
Structure & Function of the HIV-1 Envelope Protein$390,000
R56 · FY2010 · AI · contact PI
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens$234,000
R21 · FY2010 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$229,891
R21 · FY2010 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$2
R21 · FY2010 · AI · contact PI
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens$1
R21 · FY2010 · AI · contact PI
Engineered gp41 Peptides as HIV-1 Topical Microbicides$400,072
R01 · FY2009 · AI · contact PI
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides$232,429
R21 · FY2009 · AI · contact PI
Engineered gp41 Peptides as HIV-1 Topical Microbicides$400,072
R01 · FY2008 · AI · contact PI
Structure and Function of the HIV-1 Envelope Protein$390,669
R01 · FY2008 · AI · contact PI
Presentation of Structural Determinants of the 2F5 Neutralization Epitope$252,000
R21 · FY2008 · AI · contact PI
Development of N-Peptides for Use in HIV-1 Topical Microbicides$250,001
R21 · FY2008 · AI · contact PI
Stabilized gp41 Structural Motif for HIV-1 Vaccine$206,010
R21 · FY2008 · AI · contact PI
Engineered gp41 Peptides as HIV-1 Topical Microbicides$407,820
R01 · FY2007 · AI · contact PI
Structure and Function of the HIV-1 Envelope Protein$398,236
R01 · FY2007 · AI · contact PI
Stabilized gp41 Structural Motif for HIV-1 Vaccine$252,000
R21 · FY2007 · AI · contact PI
Development of N-Peptides for Use in HIV-1 Topical Microbicides$194,734
R21 · FY2007 · AI · contact PI
Structure and Function of the HIV-1 Envelope Protein$168,000
R01 · FY2007 · AI · contact PI
Engineered gp41 Peptides as HIV-1 Topical Microbicides$420,000
R01 · FY2006 · AI · contact PI
Structure and Function of the HIV-1 Envelope Protein$410,130
R01 · FY2006 · AI · contact PI
Development of N-Peptides for Use in HIV-1 Topical Microbicides$240,660
R21 · FY2006 · AI · contact PI
Structure and Function of the HIV-1 Envelope Protein$420,000
R01 · FY2005 · AI
Stabilized gp41 Trimeriration Domains for HIV-1 Vaccine$252,000
R21 · FY2005 · AI
STRUCTURE AND FUNCTION OF ECTO ADPASE/CD39$42,000
R01 · FY2005 · NS
Structure and Function of the HIV-1 Envelope Protein$420,000
R01 · FY2004 · AI
STRUCTURE AND FUNCTION OF ECTO ADPASE/CD39$254,250
R01 · FY2004 · NS
Stabilized gp41 Trimerization Domains for HIV-1 Vaccine$252,000
R21 · FY2004 · AI
Structure and Function of the SIV/CPmac gp41 Protein$254,250
R21 · FY2003 · AI
STRUCTURE AND FUNCTION OF ECTO ADPASE/CD39$254,250
R01 · FY2003 · NS
STRUCTURE AND FUNCTION OF THE HIV-1 ENVELOPE PROTEIN$301,539
R01 · FY2002 · AI
Structure and Function of the SIV/CPmac gp41 Protein$254,250
R21 · FY2002 · AI
STRUCTURE AND FUNCTION OF ECTO ADPASE/CD39$254,250
R01 · FY2002 · NS
STRUCTURE AND FUNCTION OF THE HIV-1 ENVELOPE PROTEIN$292,813
R01 · FY2001 · AI
STRUCTURE AND FUNCTION OF ECTO ADPASE/CD39$254,250
R01 · FY2001 · NS
BIOPHYSICAL &IMMUNOLOGIC ANALYSIS OF GP41 INTERMEDIATES$219,500
R21 · FY2001 · AI
STRUCTURE AND FUNCTION OF THE HIV-1 ENVELOPE PROTEIN$284,336
R01 · FY2000 · AI
STRUCTURE AND FUNCTION OF ECTO ADPASE/CD39$254,250
R01 · FY2000 · NS
BIOPHYSICAL &IMMUNOLOGIC ANALYSIS OF GP41 INTERMEDIATES$236,875
R21 · FY2000 · AI